Media

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®

Results from preclinical studies of Betalutin® in combination with rituximab in non-Hodgkin lymphoma model to be presented at ASH

Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH annual meeting in December

Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors

BONESUPPORT™ Raises $37 million (SEK 327 million) to Drive Product Sales and Deliver Further Value from CERAMENT™ Injectable Drug Eluting Bioceramic Platform

Altimmune Announces Poster Presentation of HepTcell Program at 2017 Keystone Symposia Conference

Nordic Nanovector and Heidelberg Pharma enter collaboration to develop novel antibody-drug conjugates (ADCs) targeting leukaemias